View Author
patient cancer lymph prognostic tumor base model breast model dataset status breast cancer urokinase-type plasminogen activator analysis lymph node status curve plasminogen lymph node-positive patients activator level factor node-negative <.001 value lymph node-negative patients survival adjuvant treatment variable hormone-receptor status study cancer institute prognostic factors prognostic value adjuvant treatment inhibitor multivariable breast cancer patients table lymph node-negative grade urokinase-type number group result prognostic variables 10 years menopausal status analyses histologic grade hazard effect node-positive institute hormone-receptor assay prognostic score marker article 120 months tumor size january difference prognosis journal event ratio month urokinase plasminogen activator system addition method therapy likelihood ratio test relapse-free survival histologic score subgroups relapse-free laboratory tumor characteristics
10 Most Recent Publications
|
Integrating collection of biospecimens in clinical trials: The approach of the european organization for research and treatment of cancer
(Article)
Hall, J.A. Daidone, M.G. Peters, G.J. Harbeck, N. Lacombe, D. Sleijfer, S. |
2011-06-01
|
|
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
(Article)
Schmitt, M. Mengele, K. Napieralski, R. Magdolen, V. Reuning, U. Gkazepis, A. Sweep, F.C. Brünner, N. Foekens, J.A. Harbeck, N. |
2010-11-01
|
|
DNA methylation as a biomarker in breast cancer
(Article)
Martens, J.W.M. Margossian, A.L. Schmitt, M. Foekens, J.A. Harbeck, N. |
2009-12-01
|
|
DNA methylation markers predict outcome in node-positive, Estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy
(Article)
Hartmann, O. Spyratos, F. Maier, S. Plum, A. Niemann, S. Foekens, J.A. Lesche, R. Martens, J.W.M. Harbeck, N. Dietrich, D. Fassbender, A. Schmitt, M. Eppenberger-Castori, S. VincentVuaroqueaux, None Lerebours, F. Welzel, K. |
2009-01-01
|
|
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
(Article)
Sturgeon, C.M. Duffy, M.J. Haglund, C. Harbeck, N. Hayes, D.F. Holten-Andersen, M. Klee, G.G. Lamerz, R. Looijenga, L.H.J. Molina, R. Nielsen, H.J. Rittenhouse, H. Stenman, U-H. Semjonow, A. Shih, I-M. Sibley, P. Söleformos, G. Stephan, C. Sokoll, L. Hoffman, B.R. Diamandis, E.P. Lilja, H. Brünner, N. Chan, D.W. Babaian, R. Bast Jr, R.C. Dowell, B. Esteva, F.J |
2008-12-01
|
|
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group
(Article)
Maier, S. Nimmrich, I. Schittulli, F. Kates, R. Lesche, R. Schwope, I. Kluth, A. Marx, A. Martens, J.W.M. Foekens, J.A. Schmitt, M. Harbeck, N. Koenig, T. Eppenberger-Castori, S. Bohlmann, I. Paradiso, A. Spyratos, F. Thomssen, C. Mueller, V. Nährig, J. |
2007-07-01
|
|
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers
(Article)
Schmitt, M. Mengele, K. Schueren, E. Sweep, F.C. Foekens, J.A. Brünner, N. Laabs, J. Malik, A. Harbeck, N. |
2007-03-01
|
|
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
(Article)
Martens, J.W.M. Nimmrich, I. Meijer van Gelder, M.E. Piepenbrock, C. Olek, A. Hofler, H. Kiechle, M. Klijn, J.G.M. Schmitt, M. Maier, S. Foekens, J.A. Koenig, T. Look, M.P. Harbeck, N. Model, F. Kluth, A. Bolt-de Vries, J. Sieuwerts, A.M. Portengen, H. |
2005-05-15
|
|
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
(Article)
Meijer van Gelder, M.E. Look, M.P. Peters, H.A. Schmidt, M. Brunner, N. Harbeck, N. Klijn, J.G.M. Foekens, J.A. |
2004-07-01
|
|
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
(Article)
Look, M.P. Kueng, W. Kates, R. Magdelenat, H. Martin, P.M. Beex, L.V. Windbichler, G. Janicke, F. Spyratos, F. Peyrat , J.P. Ricolleau, G. Cufer, T. Klijn, J.G.M. Brunner, N. Meijer van Gelder, M.E. Bendahl, P.O. Ulm, K. Schmitt, M. Eppenberger-Castori, S. Sweep, C.G. Fiets, W.E. Duggan, C. Blankenstein, M.A. Broet, P. Borstnar, S. Daxenbichler, G. Foekens, J.A. O'Higgins, N. Duffy, M.J. Daver, A. Manders, P. Romain, S. Quillien, V. Harbeck, N. Eppenberger, U. Putten, W.L.J. van Ferno, M. Christensen, I.J. Lisboa, B.W. Thomssen, C. |
2002-01-16
|
